RSVpreF Vaccine Found Safe for Adults Including Pregnant Individuals in Recent Evaluation

A recent evaluation of the RSVpreF vaccine has found it to be well-tolerated among adults aged 18 years and older, including both non-pregnant and pregnant individuals. The findings highlight a favorable safety profile for the vaccine, which is designed to protect against respiratory syncytial virus (RSV).

The assessment focused on the vaccine’s tolerability across different adult populations. Researchers observed that participants experienced no significant adverse reactions following vaccination, indicating its suitability for use in diverse groups. This includes pregnant individuals, who are often excluded from clinical trials due to concerns about safety during pregnancy. The study provides important data supporting the vaccine’s potential role in protecting vulnerable populations from RSV-related complications.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: August 22, 2025

Author

Mark Chiang